Systematic Review of Randomized Clinical Trials on Direct Oral Anticoagulants in Pediatric Heart Diseases
Open Access
- 1 January 2024
- journal article
- review article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 30
Abstract
Background: Direct oral anticoagulants (DOACs) have been widely applied in adults for thrombosis prophylaxis. However, the effect of DOACs in pediatric patients with congenital or acquired heart diseases who need anticoagulation therapy remains unclear. Methods: We systematically searched the databases of PubMed, Embase, and the Cochrane Library, as well as the ClinicalTrials.gov registry and the World Health Organization's International Clinical Trials Registry Platform until June 2024 to identify relevant randomized clinical trials (RCTs). If the number of included studies was less than 5, we performed a narrative review to assess the effect of DOACs in pediatric patients. Results: Four studies were included. In the UNIVERSE study, thrombotic events occurred in 2% of the rivaroxaban group and 9% of the aspirin group, with bleeding events in 36% and 41%, respectively. The ENNOBLE-ATE study showed no thromboembolic events in the edoxaban group and 1.7% in the SOC group (rate difference: −0.07%, 95% CI: −0.22 to 0.07%). Major bleeding rates were similar (rate difference: −0.03%, 95% CI: −0.18 to 0.12%). The SAXOPHONE trial showed no thromboembolic events in either group and similar major bleeding rates (−0.8%, 95% CI: −8.1 to 3.3%). In the DIVERSITY trial, 81% of dabigatran patients achieved the primary outcome versus 59.3% in the SOC group (Odds ratio: 0.342, 95% CI: 0.081–1.229). No major bleeding occurred in either group. Conclusion: Existing studies suggest that the use of DOACs hold promise as an effective and safe alternative for preventing and treating thromboembolism in pediatric patients with heart conditions.Keywords
This publication has 44 references indexed in Scilit:
- Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialThe Lancet Haematology, 2020
- Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide studyInternational Journal of Cardiology, 2020
- Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studiesThe Lancet Haematology, 2019
- Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safeOpen Heart, 2019
- Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart DiseaseCirculation, 2013
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009